Summary

Statins have been demonstrated to reduce morbidity and mortality; however, adding other lipid-modifying therapies to statin treatment has not demonstrated a clear benefit. This article presents data from the Improved Reduction of Outcomes: Vytorin (Ezetimibe/Simvastatin) Efficacy International Trial [IMPROVE-IT; NCT00202878]. The purpose of the IMPROVE-IT trial was to evaluate the clinical benefit of combination therapy with ezetimibe plus simvastatin compared with simvastatin monotherapy in lowering LDL-C levels.